SD-101: Phase I/II started

Dynavax began the open-label, dose-escalation, U.S. Phase I/II LYM-01 trial to evaluate 5 weekly intratumoral injections of 1, 2, 4 and 8 mg SD-101 given after 2 days of localized low-dose radiation i...